DuPont (DD) Q2 2026 earnings review
Clean Beat and Raise Driven by Accelerating Organic Growth
DuPont delivered a highly disciplined quarter, accelerating its organic sales growth to 4% (up from 2% last quarter) and raising full-year guidance. The transition into a focused multi-industrial company is paying off: Operating EBITDA margins expanded 40 basis points to 24.6%, and transaction-adjusted free cash flow conversion surged to 127%. While the Healthcare & Water segment experienced a slight margin compression, a surprisingly strong turnaround in Diversified Industrials more than offset the weakness. Note: All per-share metrics have been retroactively adjusted for the 1-for-3 reverse stock split executed on June 24, 2026.
🐂 Bull Case
Diversified Industrials is reversing its previous stagnation, printing 3% organic growth and driving a 70 bps margin expansion, proving the portfolio can grow even while construction markets remain tepid.
Transaction-adjusted free cash flow hit $326M (127% conversion rate), providing ample liquidity to execute the newly announced $250M Q3 share repurchase without leveraging the balance sheet.
🐻 Bear Case
Healthcare & Water is touted as DuPont's secular growth engine, but despite a 4% organic sales increase, the segment's operating margin compressed 30 bps to 30.1% due to unfavorable mix.
The company continues to battle macro headwinds, including Middle East logistics disruptions, relying heavily on its ability to push price increases and surcharges onto customers.
⚖️ Verdict: 🟢
Bullish. DuPont is executing flawlessly on the variables it can control. The accelerating organic growth, sequential guidance raise, and aggressive capital return program validate the post-spin portfolio strategy.
Key Themes
Broad-Based Organic Acceleration
DuPont's top-line is accelerating. Q2 organic sales grew 4% YoY, an acceleration from 2% in Q1 and a stark reversal from the 1% contraction seen in Q4 2025. Crucially, this growth was balanced: Healthcare & Water grew 4% organically, while Diversified Industrials grew 3%, shaking off previous quarters of construction market drag.
Diversified Industrials Lead Margin Expansion
The Diversified Industrials segment is reversing its margin compression narrative. Operating EBITDA jumped 7% YoY, and margins expanded 70 basis points to 22.1%. Management attributed this to organic volume leverage, favorable product mix, and internal productivity initiatives outstripping weak residential construction demand.
Negative Operating Leverage in Healthcare & Water
A concerning data point contradicts the narrative of Healthcare & Water being an unmitigated high-margin growth engine. Despite generating 4% organic sales growth in Q2, the segment's Operating EBITDA margin dropped 30 basis points YoY (from 30.4% to 30.1%). Management cited 'less favorable mix and growth investments.' If volume gains cannot drop to the bottom line in the highest-margin segment, the broader 150-200 bps mid-term margin expansion target is at risk.
Innovation and AI-Driven R&D Yielding Results
DuPont's commitment to maintaining a vitality index (sales from new products) of ~35% remains a structural driver of favorable pricing and mix. Key innovations, such as the rollout of advanced FilmTec elements for water filtration and the ongoing collaboration with Uncountable for AI-driven R&D, are materially accelerating development cycles and supporting the organic growth baseline.
Macroeconomic and Geopolitical Headwinds
The company continues to face a bifurcated global macro environment. Management previously guided for ~$90M in full-year input cost inflation related to Middle East conflicts. While Q2 results show they are successfully using pricing power to protect margins, sustained logistics bottlenecks in regions critical to the Water business could eventually pressure order fulfillment.
Persistent Restructuring and Asset Charges
GAAP earnings remain noisy. DuPont booked another $43 million in restructuring and asset-related charges in the first six months of 2026. While treated as 'significant items' and adjusted out of EBITDA, these are real cash and capital drags that obscure underlying profitability.
Other KPIs
Accelerating dramatically. Cash provided by operating activities (continuing ops) came in at $400M. After $76M in CapEx and backing out $2M in separation-related payments, adjusted FCF was $326M—a massive 205% increase versus 25Q2. This represents a 127% conversion rate on Adjusted Earnings, giving the company robust liquidity to fund its $250M Q3 buyback.
Up 48% YoY from $1.27 in 25Q2. The growth was driven by higher segment earnings, lower net interest expense, and a lower tax rate. Investors must note that historical EPS figures have been retroactively adjusted to reflect the 1-for-3 reverse stock split completed on June 24, 2026.
Guidance
Accelerating. The guidance assumes organic sales growth slightly above 4%, a sequential upgrade from the previous expectation of ~4% flat. Second-half sales are guided at $3.66 - $3.69 billion, implying stable mid-single-digit continuation.
Accelerating. Management raised the midpoint to $1.76 billion. H2 guidance of $890 - $910 million indicates slightly stronger absolute earnings in the back half of the year compared to H1's $862 million, reflecting confidence in pricing power and cost controls.
Accelerating. The midpoint was raised to $7.24 (split-adjusted). With $3.52 delivered in H1, the guidance requires $3.72 at the midpoint for H2. The newly announced $250M Q3 buyback will support achieving the higher end of this range.
Key Questions
Healthcare & Water Mix Pressures
Despite 4% organic growth in Healthcare & Water, margins compressed by 30 basis points. What specific product lines drove this unfavorable mix, and at what volume threshold does operating leverage turn positive for this segment?
M&A vs. Buyback Allocation
With the 127% FCF conversion rate and a fresh $250M Q3 buyback authorized, how is management currently weighing the attractiveness of aggressive share repurchases against the valuations of bolt-on M&A targets in the Healthcare and Water pipelines?
Diversified Industrials Structural Shift
Diversified Industrials posted an impressive 70 bps margin expansion despite underlying construction market weakness. How much of this margin improvement is driven by structural 80/20 initiatives versus favorable cyclical timing in Aerospace/EVs?